Remus Pharmaceuticals Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹470(38.24%)
Premium (ELP)
Remus Pharmaceuticals Limited's achieved publicly listed status following its IPO debut on May 29, 2023 at the NSE platform. The offering successfully mobilized 3,88,000 Shares, with 3,88,000 Shares allocated to corporate growth initiatives.
Investment participation occurred within the established price band of ₹1,150 to ₹1,229, starting from minimum lots of 100 shares. The subscription window from May 17, 2023 through May 19, 2023 enabled investor participation across market segments.
Share allocation was completed on May 24, 2023, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distribution of pharmaceutical products, including Active Pharmaceutical Ingredients (APIs) and finished formulations in various dosage forms. As of January 31, 2023, the company offers 429 products, with 295 registered in 13 countries and 134 under registration in 16 countries. Remus Pharmaceuticals maintains business-to-business agreements with 58 domestic and 139 international distributors, serving clients across more than 20 countries, including generic distributors, regional distributors, multinational distributors, hospitals, and clinics.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
NA
NA
- Mr. Arpit Deepakkumar Shah
- Ms. Roma Vinodbhai Shah
- Mr. Swapnil Jatinbhai Shah
- Mrs. Anar Swapnil Shah
Remus Pharmaceuticals Limited
Link Intime India Private Limited